HGF/c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
After a few attempts, he produced a model with physically plausible hydrogen bonds. Pauling then worked with Corey and Branson to confirm his model before publication. In 1954, Pauling was awarded his first Nobel Prize "for his research into the nature of the chemical bond and its application to the elucidation of the structure of complex substances" (such as proteins), prominently including the structure of the α-helix.
Most frequently seen, however, is the eastern or red-spotted newt (Notophthalmus viridescens), whose terrestrial eft form is often encountered on the open, dry forest floor. It has been estimated that salamanders represent the largest class of animal biomass in the Appalachian forests. Frogs and toads are of lesser diversity and abundance, but the wood frog (Rana sylvatica) is, like the eft, commonly encountered on the dry forest floor, while a number of species of small frogs, such as spring peepers (Pseudacris crucifer), enliven the forest with their calls. Salamanders and other amphibians contribute greatly to nutrient cycling through their consumption of small life forms on the forest floor and in aquatic habitats. Although reptiles are less abundant and diverse than amphibians, a number of snakes are conspicuous members of the fauna. One of the largest is the non-venomous black rat snake (Elaphe obsoleta obsoleta), while the common garter snake (Thamnophis sirtalis) is among the smallest but most abundant. The eastern copperhead (Agkistrodon contortrix) and the timber rattler (Crotalus horridus) are venomous pit vipers. There are few lizards, but the broad-headed skink (Eumeces laticeps), at up to 13 in (33 cm) in length, and an excellent climber and swimmer, is one of the largest and most spectacular in appearance and action. The most common turtle is the eastern box turtle (Terrapene carolina carolina), which is found in both upland and lowland forests in the central and southern Appalachians.
==== Entertainment industry ==== Glycerol is used by set decorators when filming scenes involving water to prevent an area meant to look wet from drying out too quickly. Glycerine is also used in the generation of theatrical smoke and fog as a component of the fluid used in fog machines as a replacement for glycol, which has been shown to be an irritant if exposure is prolonged.
Sources: en.wikipedia.org
Susan M Gaines is an American writer. She is the author of the novels Accidentals (2020) and Carbon Dreams (2001), and co-author with Geoffrey Eglinton and Jurgen Rullkötter of the science book Echoes of Life: What Fossil Molecules Reveal about Earth History (2009). Her short stories have been nominated twice for the Pushcart Prize. She is a former fellow of the Hanse Institute for Advanced Study in Germany. In 2018, she was awarded a Suffrage Science Award for women in science and science writers who have inspired others.
Frank Edward Bryan. Lately Chair, Belfast Metropolitan College. For services to Further Education and the Economy in Northern Ireland. James Maurice Bullick. Finance and Compliance Director and Honorary Treasurer, Belfast Harbour Commissioners and British Ports Association. For services to the Maritime Industry. Professor Emma Bunce. Professor of Planetary Plasma Physics, University of Leicester. For services to Astronomy and Science Education. Paul Jeffrey Burger. Founder and Partner, Soho Artists. For services to the Music Industry and to Charity. Ruth Catherine Margaret Busby. People and Transformational Director, Great Western Railway and Network Rail Wales and Western. For services to Diversity in the Rail Industry. Lorraine Suzette Bushell. For services to Estranged Grandparents. Dr. Samantha Jane Callan. Director and Co-Founder, The Family Hubs Network Ltd. For services to Victims of Domestic Abuse. Eunice Fay Campbell-Clark. Lately Member, City of Nottingham Council. For services to Local Government. Dr. Kathryn Myrtle Chamberlain. Lately Chief Executive, Independent Monitoring Authority for the Citizens Rights' Agreements. For Public Service. Denise Joan Christie. Chair, Elizabeth Casson Trust. For services to Occupational Therapy. Jayne Louise Clarke. Executive Principal, Pinnacle Learning Trust. For services to Further Education. The Reverend Anthony James Collins. For services to Healthcare and to the community in Harrogate and Ripon, North Yorkshire. Neil Ernest Alexander Constable. Lately Chief Executive Officer, Shakespeare's Globe. For services to Theatre.
Under CLIA, anyone, including patients and their families, laboratory personnel, and the general public, can submit anonymous complaints if there are concerns about the quality of laboratory testing. The most common CLIA complaints are concerns about a laboratory's operations, such as: unlabeled specimens, unqualified staff, record falsification, missing or incorrect test results and the confidentiality of patient information. For laboratories accredited by a laboratory Accreditation Organization (AO), complaints may be referred to the laboratory's AO. Though anyone may lodge a complaint, relatively few laboratory complaints have been filed. This may be due to a lack of publicity about complaint filing, since CLIA does not require that laboratory employees or patients be made aware of how to file a complaint, and to privacy concerns stemming from the lack of whistleblower protections. Other limiting factors include an increasing reliance on on-the-job (OTJ)- trained lab personnel who are unaware of regulatory requirements, foreign-sponsored H1b medical technologists fearing retaliatory deportation, and an aging workforce awaiting retirement. Laboratory whistleblowers may face countermeasures such as cover-ups, loss of income, position, or employment, punitive lawsuits, and attacks on their reputation, which would degrade their living conditions and dissuade them from bringing fraud to light. A June 2006 GAO report found that lab workers may file complaints infrequently due to concerns about retaliation and a lack of understanding of how to do so.
== Interactions == CNS depressants may enhance the depressant effects of hydromorphone, such as other opioids, anesthetics, sedatives, hypnotics, barbiturates, benzodiazepines, phenothiazines, chloral hydrate, dimenhydrinate, and glutethimide. The depressant effect of hydromorphone also may be enhanced by monoamine oxidase inhibitors (MAO inhibitors), first-generation antihistamines (e.g., brompheniramine, promethazine, diphenhydramine, chlorphenamine), beta blockers, and alcohol. When combined therapy is contemplated, the dose of one or both agents should be reduced.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.